Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine
Executive Summary
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.
You may also be interested in...
Finance Watch: $2.2bn In New Funding Sources In February, So Far
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Coronavirus Update: Novavax Launches Phase III Trial In UK As Virus Surges Back
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
India’s Draft Guidelines For COVID-19 Vaccines Follow WHO, US Lead
India has rolled out draft guidelines for development of vaccines with special focus on COVID-19 vaccines, drawing from those of other regulatory bodies and the WHO. Experts suggest the primary efficacy endpoint of minimum 50% is acceptable given that vaccines against respiratory diseases are difficult to develop though not necessarily enough to snuff out a pandemic.